Member Info for Cuddles48

Paul just commented that they have 2 dozen projects in play with fee agreements.

The 16460 is my buy this morning will be another similar amount at 114.40

At least I am putting my money where my mouth is

Why don’t you listen to the meet the company this afternoon. May get some clarification on all that.

You can always ask the question.

I’ve had it from the horses mouth

Read the RNS of 12th ‘Nov stating that the results would be 20/11 and that there will be a presentation of meet the company on Monday 23/11 at 15.00.

I have already sent in multiple questions and I already have confirmation they are working for multiple companies circa at least 8 that they have fee agreements where they will get royalties if drugs meet certain milestones and many are already in trials at various stages.

I have been informed we will learn more next year as it is part of 2021 IR

That’s why I say it’s like a multiple bet on a variety of drugs companies trialing new drugs from Antibodies

We already know that 7 of the top 10 drugs by revenue are from antibodies

So just imagine if any of FAB’s customers with whom they have fee arrangements get a drug successfully through trials to market the potential revenue could surpass anything they have in place so far. For no further work.

Multiple antibodies in trials.

They have also confirmed to me they are working with companies developing vaccines.

So that’s another potential windfall if they also are few arrangements.

So much more to come in my opinion.

Massively under the Radar here.

I am sure The spread is one of the Main issues putting off new investors it’s time the broker tried to help improve this.

FAB is like a good each way EY on multiple drug companies. And the beauty is we only need the odd one new drug to come to market to reap rewards. Imagine if multiple drugs get to market. So much potential and a great multiple play.

This has been highlighted as a current Covid investment but that couldn’t be further feom the truth. Imo.

Quite agree

And I believe on Monday we will get a much clearer picture of the future plans and maybe some confirmation that not only are we helping drug companies who are trialing new antibody drugs for future mass use but also that we are helping those drug companies that are preparing new vaccines to combat the dreaded Covid pandemic.

We may also get a bit more of an indication as to how many of FAB’s customers with whom we have fee agreements on drug results are currently in the midst of live trials. This way the market may be able to assess the huge potential that is waiting in the wings for Fusions future revenue.

Then the rerate may begin.

Paul Kerr’s post on Linkedin

Huge congratulations to the team at NBE-Therapeutics AG on reaching clinical trials with its lead program NBE-002 targeting ROR1, for triple negative breast cancer (TNBC) and other solid tumors. This is a fantastic achievement and from all Fusion Antibodies we wish you every success with this important stage in the journey!

Read between the lines clearly someone FAB must be working with. So highly likely that they have an NDA and possibly a potential royalty fee if this gets to market.

Just imagine all the other potential royalties they might get from the 8 or so drugs going through trials.

Well I have bought 1.5 million in the past two months. Very happy to hold for five years and make some serious money.

I don’t think the market understands how many potential drugs they have a carry on that are already in trials

Just look at FAB on Linkedin see the posts and read between the lines.

Looking forward to plenty upside.